The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune profiling to identify predictive biomarkers and highlights the potential efficacy of IL-6R blockade in checkpoint inhibitor–related myocarditis.
 
Michel Obeid
Honoraria - BMS GmbH & Co. KG
 
Sarah Boughdad
No Relationships to Disclose
 
Douglas Daoudlarian
No Relationships to Disclose
 
Robin Bartolini
No Relationships to Disclose
 
Sofiya Latifyan
No Relationships to Disclose
 
Jacqueline Doms
No Relationships to Disclose
 
Hasna Bouchaab
Honoraria - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Janssen Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Janssen Oncology (Inst); Merck (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); AstraZeneca (Inst); Janssen Oncology (Inst); PharmaMar (Inst); Takeda (Inst)
 
Karim Abdelhamid
No Relationships to Disclose
 
Nabila Ferahta
No Relationships to Disclose
 
Nuria Mederos
No Relationships to Disclose
 
Victor Joo
No Relationships to Disclose
 
Antonia Stamatiou
No Relationships to Disclose
 
Mencarelli Mencarelli
No Relationships to Disclose
 
Nicolas Etienne
No Relationships to Disclose
 
Khalil Zaman
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi (Inst); Gilead Sciences (Inst); Seagen (Inst)
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Pierre Fabre (Inst); Roche (Inst)
Other Relationship - Daiichi Sankyo Europe GmbH (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
 
Matthieu Perreau
No Relationships to Disclose
 
Craig Fenwick
No Relationships to Disclose
 
Keyvan Shabafrouz
No Relationships to Disclose
 
Giuseppe Pantaleo
No Relationships to Disclose
 
Solange Peters
Honoraria - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Foundation Medicine (Inst); GlaxoSmithKline; Illumina (Inst); Imedex (Inst); Incyte (Inst); Ipsen (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Biocartis (Inst); Bioinvent (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HUTCHMED (Inst); Illumina (Inst); Incyte (Inst); Ipsen (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Nuvation Bio (Inst); Nykode Therapeutics (Inst); Nykode Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Promontory Therapeutics (Inst); Qlucore (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Zymeworks (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President